Literature DB >> 6766788

Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy.

J L Barker, E D Montague, L J Peters.   

Abstract

From 1948 to 1972, 69 patients with inflammatory carcinoma of the breast were treated with irradiation alone. Because of a 46% incidence of local-regional failure, twice daily fractionated irradiation was given in 1972 to 11 patients; a decrease in local-regional failures (27%) was achieved. From 1973 through December 1976, preirradiation multidrug chemotherapy was added to the twice daily fractionated irradiation of 31 patients. Analysis of all patients with a minimum two-year follow-up demonstrates that chemotherapy does not improve local-regional control or freedom from disease rates, but does delay appearance of distant metastases.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6766788     DOI： 10.1002/1097-0142(19800215)45:4<625::aid-cncr2820450402>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  10 in total

1.  Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.

Authors:  E H Koh; A U Buzdar; F C Ames; S E Singletary; M D McNeese; D Frye; F A Holmes; G Fraschini; V Hug; R L Theriault
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.

Authors:  R A Sorace; C S Bagley; A S Lichter; D N Danforth; M W Wesley; R C Young; M E Lippman
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

3.  Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.

Authors:  Zsolt Horváth; László Torday; Erika Hitre; Erna Ganofszky; Eva Juhos; Ferenc Czeglédi; László Urbán; Csaba Polgár; István Láng; Sándor Eckhardt; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2010-12-14       Impact factor: 3.201

4.  Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy.

Authors:  R L Bauer; E Busch; E Levine; S B Edge
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

5.  Can sequential administration minimise the cost of high dose chemotherapy? An economic assessment in inflammatory breast cancer.

Authors:  Patricia Marino; Anne-Gaelle Le Corroller; Thao Palangié; Maud Janvier; Michel Fabbro; Laurent Molinier; Thierry Delozier; Alain Livartowski; Jean-Paul Moatti; Patrice Viens
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.

Authors:  Ian J Bristol; Wendy A Woodward; Eric A Strom; Massimo Cristofanilli; Delora Domain; S Eva Singletary; George H Perkins; Julia L Oh; Tse-Kuan Yu; Welela Terrefe; Aysegul A Sahin; Kelly K Hunt; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-24       Impact factor: 7.038

7.  Multiple fraction-per-day radiotherapy for patients with brain stem tumors.

Authors:  M E Hebert; E C Halperin; W J Oakes; O B Boyko
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

8.  Increased incidence of lung metastases of sarcoma 276 bearing XVII/Berlin mice after total body irradiation and BCG.

Authors:  W Arnold; A Graffi
Journal:  Clin Exp Metastasis       Date:  1983 Apr-Jun       Impact factor: 5.150

9.  Inflammatory breast cancer: is it really a separate entity?

Authors:  As Bastawisy; Rm Gaafar; Ss Eisa; Gm Amira; Mh Helal
Journal:  Ecancermedicalscience       Date:  2012-04-12

10.  Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.

Authors:  D Genet; C Lejeune; P Bonnier; Y Aubard; L Venat-Bouvet; D J Adjadj; J Martin; J L Labourey; A Benyoub; P Clavère; V Lebrun-Ly; P Juin; L Piana; N Tubiana-Mathieu
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.